Empagliflozin for kidney health in African American veterans
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is testing whether the drug empagliflozin (Jardiance) can help protect the kidneys of African American veterans who already have some kidney damage but do not have diabetes. The goal is to see if the drug can reduce damage at the cellular level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an African American veteran.
- You are 18 years or older.
- You have some kidney damage but not severe (eGFR between 20 and 89, and if your eGFR is 60-89, you must have some protein in your urine).
- Your blood pressure is controlled (140/90 or lower).
- You do not have diabetes.
- Your body mass index (BMI) is between 18 and 39.9.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This study tests a medication called finerenone to see if it helps protect the kidneys in African American veterans with diabetic kidney disease. The goal is to slow down kidney damage and improve overall kidney health.
This study tests whether a medication called empagliflozin (a type of drug that helps protect the kidneys) can improve blood vessel health in people with chronic kidney disease who do not have diabetes. It may help slow kidney decline and reduce heart risks.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.